Evidence map›Paper›PMID 39239332›Full record

ArticleJACC. CardioOncology2024

Echocardiography-Guided Radiofrequency Ablation for Cardiac Tumors.

Junzhe Huang, Changhui Lei, David H Hsi, Minjuan Zheng, Hui Ma, Shengjun Ta, Rui Hu, Chao Han, Wenxia Li, Jing Li and 10 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. CardioOncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02815553 (Cardiac Tumors Interventional （Radio Frequency/Laser Ablation）Therapy), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02815553 naunknown statusnot on this map

Cardiac Tumors Interventional （Radio Frequency/Laser Ablation）Therapy

TypeinterventionalSponsorXijing HospitalRan2016 to 2022Enrolled10ConditionsCardiac TumorsArmsDirect Transthoracic Cardiac Tumor Radio Frequency Ablation Therapy, Direct Transthoracic Cardiac Tumor Laser Ablation Therapy
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Junzhe HuangXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Changhui LeiXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
David H HsiHeart & Vascular Institute, Stamford Hospital, Connecticut, USA.
Minjuan ZhengXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Hui MaXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Shengjun TaXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Rui HuXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Chao HanXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Wenxia LiXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Jing LiXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Dong QuXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Fangqi RuanXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Jing WangXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Bo WangXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Xueli ZhaoXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Jiao LiuXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Lina ZhaoXijing Ultrasound Interventional Treatment Center for Cancer, Department of Radiotherapy, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Zhe WangXijing Ultrasound Interventional Treatment Center for Cancer, Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Jian YangXijing Ultrasound Interventional Treatment Center for Cancer, Department of Cardiac Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Liwen LiuXijing Ultrasound Interventional Treatment Center for Cancer, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with cardiac tumors may present challenges for surgical resection due to poor clinical condition. Echocardiography-guided transapical radiofrequency ablation for cardiac tumors (TARFACT) potentially offers a less invasive palliative therapy option. Objectives: This study aimed to evaluate the safety and efficacy of TARFACT. Methods: Five patients with cardiac tumors (mucinous liposarcoma, myocardial hypertrophy with inflammatory cell infiltration mass, fibrous tissue tumor hyperplasia, myocardial clear cell sarcoma, and cardiac rhabdomyoma) were included. All patients underwent TARFACT and were assessed with electrocardiogram, echocardiographic imaging, biochemical analysis, and pathological confirmation. Results: The median follow-up for all patients was 9 (range 4-12) months. Three surviving patients were alive at their last follow-up (9, 12, and 12 months, respectively), whereas 2 patients with late-stage tumors survived 6 months and 13 months after TARFACT, respectively. After TARFACT, all patients showed significant reductions in tumor size: the mean length decreased from 6.7 ± 2.0 cm to 4.7 ± 1.8 cm ( Conclusions: TARFACT is a novel palliative treatment option for cardiac tumors, reducing accessible tumors and improving clinical symptoms in a preliminary group of patients. (Cardiac Tumors Interventional [Radio Frequency/Laser Ablation] Therapy [CTIH]; NCT02815553).

Indexed as

cardiac tumorstransapical radiofrequency ablation for cardiac tumors TARFACTtumor debulking ablation

Identifiers

PMID39239332
PMCPMC11371935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.